	Application No.	Applicant(s)
Notice of Allowability	09/426,548	ROBBINS ET AL.
	Examiner	Art Unit
	Joseph T. Woitach	1632
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>June 23, 2004</u> .		
2. The allowed claim(s) is/are 2,3 and 9.		
3. The drawings filed on are accepted by the Examiner.		
 4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☐ hereto or 2) ☐ to Paper No./Mail Date (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date 		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892)	5. ☐ Notice of Informal P	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	(PTO-413),
Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date	· `	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit		nt of Reasons for Allowance
of Biological Material	9.	

DETAILED ACTION

This application claims benefit to provisional application 60/105,180, filed October 22, 1998.

Applicants amendment filed June 23, 2004, has been received and entered. Claims 2, 3 and 9 have been amended. Claims 2, 3 and 9 are pending and currently under examination.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kathleen A. Tyrrell on September 1, 2004.

The application has been amended as follows:

Amend claim 9 to read

9. An oligonucleotide probe fully complimentary to a sequence comprising a hMLH1 mutant 1, a hMSH2 mutant 1, a hMSH2 mutant 2 or a hMSH2 mutant 3.

Art Unit: 1632

Joseph T. Woitach

Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The instant specification teaches genetic variants of hMLH1 and hMSH2 that are associated with hereditary non-polyposis colorectal cancer. The sequences of hMLH1 and hMSH2 are provided and the specific mutations claimed are set forth in Table 1 and specifically defined on page 17, lines 1-16. As indicated previously, the specific mutations are free of the art of record because the art failed to teach each of the specific mutations. Moreover, while these genes have been associated with colorectal cancer and other variants have been described in the prior art, this is the first disclosure of the claimed sequences being specifically associated with a form of colorectal cancer.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (571) 272-0739.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached at (571) 272-0734.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Dianiece Jacobs whose telephone number is (571) 272-0532.

JOSEPH WOITACH PATENT EXAMINED